04:06 PM EDT, 04/01/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) administered the first patient dose in an early trial of TLX300-CDx, also known as olaratumab, to treat advanced metastatic soft tissue sarcoma.

The trial aims to evaluate the drug's safety, how it moves through and interacts with the body, and the distribution of radiation within tissues, as well as determine the optimal dose, the company said Tuesday in a statement.

Additionally, the trial will help finalize the choice of therapeutic radionuclide to pair with the drug candidate, the company said.

TLX300-CDx hasn't received marketing authorization in any jurisdiction, the company said.

Price: 16.71, Change: -0.05, Percent Change: -0.30